Ophthalmology Innovation Summit @ AAO Logo 2014 OIS@AAO
October 16, 2014 | Chicago, IL
Register

Thank you to all that attended! Hope to see you all at the 2015 OIS@AAO in Las Vegas.

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

Palmer House Hilton

Reserve a Room for OIS@AAO 2014:

Discounted room rates have been negotiated exclusively for AAO 2014 Attendees. There is limited inventory available at these special rates so we urge you to book today!

Start Networking Today… Get The App!

OIS App for iPhone OIS App for iPad OIS App for Android

Or access the mobile or desktop version.

Latest News

Tom Frinzi of WaveTec Vision Systems

WaveTec Vision Systems

Tim Willis of TearScience

TearScience

Barry Cheskin of PowerVision

PowerVision

Quinton Oswald of Neurotech

Neurotech

Robert Butchofsky of Mati Therapeutics

Mati Therapeutics

Ronen Castro of IOPtima

IOPtima

Max Ostermeier of Implandata Ophthalmic Products GmbH

Implandata Ophthalmic Products GmbH

John Maroney of ForSight VISION5

ForSight VISION5

David Muller of Avedro

Avedro

Russell Trenary of InnFocus

InnFocus

Dan Myers of Alimera Sciences

Alimera Sciences

ois

Device, Delivery, & Diagnostic Company Showcase

jeff george

Alcon’s George Shares Passion for Ophthalmology

Untitled-1

Biopharma Companies of All Stages Shine in OIS Showcase

hoffman

Eye Companies Helping Health Care Stand Out

second acts

CEOs Share Their ‘Second Acts’ On Way to Building Successful Companies

fda

FDA Division Directors Detail How Agency Adapts to Innovation

ois

Digital Health Companies Poised to Grow

David W. Parke Pic

AAO Sees Good and Bad in Consolidation

Matthew J. McMahon Pic

The NEI’s Role in Innovation

Franz Obermayr of Panoptes

Panoptes Developing Inhibitor For Local Treatments In Ocular Disease

Shelly Boyd of Translatum Medicus

Translatum Medicus Developing Option To Treat Dry AMD

Charlie McDermott of Kala Pharmaceuticals

Kala Pharmaceuticals Offers Glimpse Into Preclinical Pipeline

John Freshly of ONL

ONL Therapeutics Develops Novel Mechanism To Attack Fas Receptor Apoptosis

Vicente Anido of Aerie Pharaceuticals

Aerie Pharmaceuticals With Two ROCK Inhibitors In Development

Henry Hsu of Allysta

Allysta Pharmaceuticals Developing Multi-Kinase Inhibitor To Treat Glaucoma

Amarpreet Sawhney of Ocular Therapeutix

Ocular Therapeutix

Michael O'Rourke of GrayBug

GrayBug With Preclinical Work On Microparticle Anti-VEGF Compound GB-102

Ed Timm of Mobius Therapeutics

Mobius Therapeutics Investigates Extending Mitosol Platform

Bernhard Gunther of Novaliq

Novaliq GmbH Using Semifluorinated Alkanes To Improve Solubility Of Topical Agents

Paul Rubin of Xoma

Monoclonal Antibody Company XOMA Corp. Shares New Strategy

David R. Guyer of Ophthotech

Ophthotech Shares Late-Stage Progress of Fovista

Vicken Karageozian of Allegro

Allegro Gives Phase II News on Luminate

Thomas W. Chalberg of Avalanche

Avalanche Biotechnologies Gives Ocular BioFactory Tour

Jesper J. Lange of MC2

MC2 Biotek Group Offers Insights on PAD

google

How Alcon and Google Could Change The Contact Lens

Amarpreet Sawhney @ OIS

Studies Underway For Sustained-Release Injectable Anti-VEGFs For Posterior Diseases

Ronen Castro @ OIS

CLASS Procedure May Be Safe Alternative To Trabeculectomy

Vicente Anido @ OIS

Glaucoma Products In The Pipeline For Aerie

Noel Alpins @ OIS

CorT Measures Total Corneal Power

Eliot J. Lazar MD

Innovation Summit Brings Industry, Investors, Ophthalmologists Together

Jai G. Parekh @ OIS

Nanotechnology Company Developing Better Drug Delivery To The Eye

Robert Butchofsky @ OIS

Sustained Drug Delivery Platform May Eliminate Daily Administration

Charles McDermott @ OIS

Kala Highlights Investigational KPI-121

Gregory Hageman @ OIS

Gene Therapy On The Tipping Point

Monty Montoya @ OIS

Ophthalmology, Technology Intersect At OIS

Vicken Karageozian @ OIS

Allegro Begins Phase 2 Study For Treatment Of DME

Angel Investor Eric Kanter

How Do You Talk To An Angel?

Ophthalmology Leaders Speak To Strength Of Sector

Ophthalmology Leaders Speak To Strength Of Sector

David Muller Panel

Avedro Broadens Cross-Link Product Line

Page 1 of 212
Share with your friends










Submit